Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.94 |
| ▸ | MMP13 | P45452 | 16/20 | 0.55 |
| ▸ | MMP9 | P14780 | 6/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MMP16 | P51512 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25130 | 0.99 | MMP1 (0.96) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL26986 | 0.97 | MMP1 (1.00) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL13556928 | 0.91 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6876444 | 0.91 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL26434 | 0.90 | MMP1 (0.83) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL4783958 | 0.89 | MMP1 (0.79) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL3914710 | 0.89 | MMP1 (0.78) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6818064 | 0.89 | MMP1 (0.78) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6699509 | 0.89 | MMP1 (0.84) | MMP1MMP13MMP9MMP2MMP8 | |
| SCHEMBL6813091 | 0.88 | MMP1 (0.76) | MMP1MMP13MMP9MMP2MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | claimed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1003720-B1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | disclosed |
| US-6214872-B1 | ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS | PFIZER INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |